Active Filter(s):
Details:
The combination will create one of the largest and fastest growing UK pharma companies and accelerated growth in current and future product portfolio, especially in healthcare (leading asset Akizza having gestodene/ethinylestradiol combination) in the UK and internationally.
Lead Product(s): Gestodene,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Akizza
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Aspire Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 03, 2022